Article Text

Download PDFPDF
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer
  1. S R Lakhani
  1. The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Mary-Jean Mitchell Green Building, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, UK
  1. Professor Lakhani lakhani{at}icr.ac.uk

Abstract

Breast cancer is a common solid malignancy in women. Over the past decade, much progress has been made in understanding the biology of breast cancer. The use of molecular and immunohistochemical techniques is providing insights that will allow us to tailor the management of patients with breast cancer. In this review, progress in the understanding of lobular carcinoma in situ and atypical ductal hyperplasia, the use of the molecular marker CerbB2, and information gained from the morphological analysis of tumours arising in patients with BRCA1 and BRCA2 mutations is discussed. J Clin Pathol: Mol Pathol(J Clin Pathol: Mol Pathol 2001;54:281–284)

  • breast cancer
  • lobular carcinoma in situ
  • atypical ductal hyperplasia
  • CerbB2,
  • BRCA1 mutation
  • BRCA2 mutation
  • molecular markers

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes